Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab versus placebo as adjuvant therapy in ctDNA-positive high-risk muscle-invasive bladder cancer after cystectomy
jRCT2031210016Phase 3Active, not recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in transitional cell carcinoma of the bladder (TCC) and muscle-invasive bladder cancer (MIBC) comparing Atezolizumab with Placebo (2 arms). Primary endpoint: Disease-free survival. Started Sep 2021; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
transitional cell carcinoma of the bladder (TCC)muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on jRCT2031210016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210016.